No significant difference observed in KEAP1-mutated vs. WT NSCLC pateints.Pembrolizumab: 17 vs. 16.9 months; platinum-based chemotherapy: 8.9 vs. 12.2 months. This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.